75
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

The anticancer drug bleomycin investigated by density functional theory

&
Pages 1233-1239 | Received 01 Jun 2006, Accepted 01 Nov 2006, Published online: 04 Mar 2011
 

Abstract

Activated bleomycin (ABLM) is an oxygenated iron drug complex which embodies the drug's DNA-cleaving activity. This activity is exercised on DNA, if present, but if DNA is absent, the drug itself is inactivated. We have employed quantum density functional theory (DFT)-based methods to investigate (i) the structure of the Fe(II)BLM complex that is first formed in the human body after drug's administration, and (ii) the activation mechanism of the O–O bond present in the ABLM. We have identified the controversial second axial ligand as the endogenous oxygen atom of the carbamoyl group. Our first principles molecular dynamics (MD) simulations indicate a homolytic cleavage as the mechanism of the O–O bond activation in the ABLM complex.

Acknowledgements

We thank Prof. U. Roethlisberger and members of her group at EPFL for providing and introducing us to the QM/MM hybrid code. We acknowledge the CYTTRON consortium for partially financing this project. The use of supercomputer facilities was sponsored by the Stichting Nationale Computer Faciliteiten (NCF), with financial support from Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.